Considerations for the use of imaging tools for phase II treatment trials in oncology
Quality Assurance Review Center; Department of Radiation Oncology
Health Services Administration | Neoplasms | Oncology | Radiology
In the context of assessing tumor response, imaging tools have the potential to play a vital role in phase II and III treatment trials. If the imaging test is able to predict potential phase III success in a reliable fashion, it would be a useful tool in phase II trial design as it may provide for a more rapid and timely response assessment. The benefits and challenges of using anatomic imaging measures as well as the promising molecular imaging measures, primarily fluorodeoxyglucose-positron emission tomography, are discussed here. The general issues related to successful implementation of advanced imaging in the context of phase II treatment trials are discussed.
DOI of Published Version
Epub 2009 Mar 10. Link to article on publisher's site
Clinical cancer research : an official journal of the American Association for Cancer Research
Shankar LK, Van den Abbeele A, Yap J, Benjamin R, Scheutze S, FitzGerald TJ. (2009). Considerations for the use of imaging tools for phase II treatment trials in oncology. IROC Rhode Island (QARC) Publications. https://doi.org/10.1158/1078-0432.CCR-08-2030. Retrieved from https://escholarship.umassmed.edu/qarc/39